1. Zozulya N.I., Kumskova M.A. Protocol of diagnosis and treatment of hemophilia. In: Diagnostic algorithms and treatment protocols for diseases of the blood system. Ed. by Academician V.G. Savchenko . M.: National Medical Research Center for Hematology, 2018. Vol. 1. Pp. 333-375. (In Russ.).
2. Mamaev A.N. Coagulopathies: a guide. M.: GEOTARMedia, 2012. 264 p. (In Russ.).
3. Tjarnlund-Wolf A., Lassila R. Phenotypic characterization of haemophilia B - understanding the underlying biology of coagulation factor IX. Haemophilia 2019;25(4):567-74. https://doi.org/10.1111/hae.13804.
4. Weyand A.C., Pipe S.W. New therapies for hemophilia. Blood 2019;133(5):389-98. https://doi.org/10.1182/blood-2018-08-872291.
5. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014;20 Suppl 4:99-105. https://doi.org/10.1111/hae.12405.
6. Mannucci P.M., Macuso M.E. Investigational drugs for coagulation disorders. Expert Opin Invest Drugs 2013;22(8):945-53. https://doi.org/10.1517/13543784.2013.798302.
7. Oldenburg J., Albert T. Novel products for haemostasis - current status. Haemophilia 2014;20(Suppl 4):23-8. https://doi.org/10.1111/hae.12428.
8. Metzner H.J., Weimer T., Kronthaler U., Lang W., Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. J Thromb Haemost 2009;102(4):634-44. https://doi.org/10.1160/TH09-04-0255.
9. Santagostino E. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thromb Res 2016 ;141 Suppl 3:S5-8. https://doi.org/10.1016/S0049-3848(16)30415-7.
10. Pipe S.W. New therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2016;2016(1):650-656. https://doi.org/10.1182/asheducation-2016.1.650.
11. Shapiro A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin Biol Ther 2013;13(9):1287-97. https://doi.org/10.1517/14712598.2013.819339.
12. Ducore J.M., Miguelino M.G., Powell J.S. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Rev Hematol 2014;7(5):559-71. https://doi.org/10.1586/17474086.2014.951322.
13. Santagostino E., Martinowitz U., Lissitchkov T., Pan-Petesch B., Hanabusa H., Oldenburg J., Boggio L., Negrier C., Pabinger I., von Depka Prondzinski M., Altisent C., Castaman G., Yamamoto K., Alvarez-Roman M.-T., Voigt C., Blackman N., Jacobs I.; PROLONG-9FP Investigators Study Group. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016;127(14):1761-9. https://doi.org/10.1182/blood-2015-09-669234.
14. Pelland-Marcotte M.-C., Carcao M.D. Hemophilia in a changing treatment landscape. Hematol Oncol Clin North Am 2019;33(3):409-23. https://doi.org/10.1016/j.hoc.2019.01.007.
15. Chan A.K., Alamelu J., Barnes C., Chuansumrit A., Garly M.L., Meldgaard R.M., Young G. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost 2020;4(7):1101-13. https://doi.org/10.1002/rth2.12412.
16. Kenet G., Chambost H., Male C., Lambert T., Halimeh S., Chernova T., Mancuso M. E., Curtin J., Voigt C., Li Y., Jacobs I., Santagostino E. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Thromb Haemost 2016;116(4):659-68. https://doi.org/10.1160/TH16-03-0179
17. Santagostino E., Negrier C., Klamroth R., Tiede A., Pabinger-Fasching I., Voigh C., Jacobs I., Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012;120(12):2405-11. https://doi.org/10.1182/blood-2012-05-429688.
18. Mancuso M.E., Lubetsky A., Pan-Petesch B., Lissitchkov T., Nagao A., Seifert W., Li Y., Santagostino E. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost 2020;18(5):1065-74. https://doi.org/10.1111/jth.14778.
19. Hermans C., Marino R., Lambert C., Mangles S., Sommerer P., Rives V., Maro G., Malcangi G. Real-world utilization and bleed rates in patients with haemophilia B who switched to recombinant factor IX Fusion Protein (rIX-FP): a retrospective international analysis. Adv Ther 2020;37(6):2988-98. https://doi.org/10.1007/s12325-020-01300-6.
20. Order of the Ministry of Health of the Russian Federation from 20.12.2012 № 1238n “On approval of the standard primary health care to children with hemophilia A, hemophilia B (In prevention of bleeding or hemorrhage in uncomplicated and after successful induction of immune tolerance)” (Registered with the Ministry of Justice of the Russian Federation 19.02.2013 № 27187). (In Russ.).
21. Standard of care for patients with hereditary factor VIII deficiency, hereditary factor IX deficiency, and Willebrand’s disease. Approved by the Order of the Ministry of Health and Social Development of the Russian Federation from 14.11.2007 № 705. (In Russ.).
22. Pouplard C., Galinat H., Ternisien C., Jouvan F.B., De Maistre E., Duchemin J., Flaujac C., Hezard N., Grand F., Le Cam-Duchez V., Marlu R., Mourey G., Nedelec F., Pineau-Vincent F., Repesse Y., Stepanian A., Szymezak J., Voisin S., Voyer A. L., Jeanpierre E., Lasne D.; French Study Group on Laboratory Management of bleeding disorders (BIMHO group). Multicentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion®). Haemophilia 2019;25(5):e327-30. https://doi.org/10.1111/hae.13812.
23. Tripodi A., Chantarangkul V., Novembrino C., Peyvandi F. Advances in the treatment of hemophilia: implications for laboratory testing. Clin Chem 2019;65(2):254-62. https://doi.org/10.1373/clinchem.2017.284356.
Email this article 
